



Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	May 21, 2012, November 23, 2015, October 21, 2019

XGEVA® (denosumab)

LENGTH OF AUTHORIZATION: Up to six months

REVIEW CRITERIA:

- Patient must be ≥ 18 years old, **or adolescent with skeletal maturity in unresectable giant cell tumor of the bone.**
- CONFIRMATION OF ONE OF THE FOLLOWING DIAGNOSES:
 - **Multiple Myeloma**
 - Bone metastases from solid tumors confirmed by progress notes or medical records.
 - Giant Cell Tumor of the bone that is unresectable or resection will likely cause severe morbidity.
 - Hypercalcemia of malignancy refractory to bisphosphonate therapy.

DOSING & ADMINISTRATION:

Multiple Myeloma or Bone Metastasis from solid tumors: 120 mg subcutaneously every 4 weeks.

Bone or Hypercalcemia of Malignancy: 120 mg subcutaneously every week for 3 weeks then starting week 5, 120mg subcutaneously every 4 weeks.

Giant Cell Tumor for adolescents with skeletal maturity and adults: 120 mg subcutaneously every week for 3 weeks then starting week 5, 120mg subcutaneously every 4 weeks.